Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3101
Direxion Daily Energy Bull 2X ETF
ERX
$252M
| $386K | ﹤0.01% |
+5,800
| New | +$385K |
|
3102
National Fuel Gas
NFG
$7.81B
| $386K | ﹤0.01% |
6,100
-177,200
| -97% | -$11.4M |
|
3103
Tiptree Inc
TIPT
$674M
| $385K | ﹤0.01% |
27,800
-15,500
| -36% | -$200K |
|
3104
Bio-Rad Laboratories Class B
BIO.B
| $384K | ﹤0.01% |
1,900
-200
| -10% | -$81.7K |
|
3105
UroGen Pharma
URGN
$2.32B
| $384K | ﹤0.01% |
43,300
+200
| +0.5% | +$1.89K |
|
|
VLDR
3106
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
| $384K | ﹤0.01% |
519,700
+53,700
| +12% | +$50.7K |
|
3107
Berkshire Hathaway Class B
BRK.B
$1.08T
| $383K | ﹤0.01% |
1,246
-478,454
| -100% | -$142M |
|
3108
Rigetti Computing
RGTI
$6.24B
| $383K | ﹤0.01% |
524,694
+150,994
| +40% | +$216K |
|
|
BASE
3109
DELISTED
Couchbase
BASE
| $382K | ﹤0.01% |
28,800
+2,300
| +9% | +$29.8K |
|
3110
Castor Maritime
CTRM
$22.1M
| $381K | ﹤0.01% |
34,035
+1,795
| +6% | +$22.4K |
|
3111
PLAYSTUDIOS Inc
MYPS
$63.7M
| $380K | ﹤0.01% |
97,900
+4,500
| +5% | +$18.1K |
|
|
MNTX
3112
DELISTED
Manitex International, Inc.
MNTX
| $380K | ﹤0.01% |
94,940
+28,400
| +43% | +$131K |
|
3113
Weyco Group
WEYS
$430M
| $379K | ﹤0.01% |
17,926
-4,300
| -19% | -$103K |
|
3114
Vanguard S&P 500 Value ETF
VOOV
$6.81B
| $378K | ﹤0.01% |
+2,700
| New | +$373K |
|
3115
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
$19.8B
| $378K | ﹤0.01% |
8,100
-429,600
| -98% | -$20.5M |
|
|
CYT
3116
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $378K | ﹤0.01% |
229,193
-37,628
| -14% | -$60.4K |
|
3117
American Superconductor
AMSC
$1.54B
| $376K | ﹤0.01% |
102,189
-34,700
| -25% | -$136K |
|
3118
CBIZ
CBZ
$2.96B
| $375K | ﹤0.01% |
+8,000
| New | +$380K |
|
|
TOUR
3119
Tuniu
TOUR
$54M
| $374K | ﹤0.01% |
24,773
-3,890
| -14% | -$42.8K |
|
3120
Comscore
SCOR
$92.4M
| $372K | ﹤0.01% |
16,018
-4,679
| -23% | -$121K |
|
3121
Zevra Therapeutics
ZVRA
$664M
| $372K | ﹤0.01% |
81,000
+9,100
| +13% | +$46.2K |
|
3122
Kaltura
KLTR
$243M
| $369K | ﹤0.01% |
214,500
-12,600
| -6% | -$23.2K |
|
3123
Invesco S&P MidCap Momentum ETF
XMMO
$7.69B
| $369K | ﹤0.01% |
+4,900
| New | +$376K |
|
3124
State Street SPDR Portfolio TIPS ETF
SPIP
$1.01B
| $368K | ﹤0.01% |
14,300
-45,800
| -76% | -$1.18M |
|
3125
Applied Optoelectronics
AAOI
$12.6B
| $367K | ﹤0.01% |
194,200
-10,700
| -5% | -$25.4K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.